These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 31766881)
1. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer. Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881 [No Abstract] [Full Text] [Related]
2. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF Zeng Q; Deng Y; Zhang L; Wang W Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623 [TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606 [No Abstract] [Full Text] [Related]
5. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771 [No Abstract] [Full Text] [Related]
6. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Iyer PC; Dadu R; Ferrarotto R; Busaidy NL; Habra MA; Zafereo M; Gross N; Hess KR; Gule-Monroe M; Williams MD; Cabanillas ME Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986 [TBL] [Abstract][Full Text] [Related]
7. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411 [TBL] [Abstract][Full Text] [Related]
8. Acquired Secondary RAS Mutation in BRAF Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548 [No Abstract] [Full Text] [Related]
9. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975 [TBL] [Abstract][Full Text] [Related]
10. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature. Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167 [TBL] [Abstract][Full Text] [Related]
11. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells. Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799 [TBL] [Abstract][Full Text] [Related]
12. Case report: Complete response of an anaplastic thyroid carcinoma patient with Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S Front Immunol; 2023; 14():1178682. PubMed ID: 37122752 [TBL] [Abstract][Full Text] [Related]
13. Combination Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898 [No Abstract] [Full Text] [Related]
14. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma. Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921 [TBL] [Abstract][Full Text] [Related]
15. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF White PS; Pudusseri A; Lee SL; Eton O Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135 [TBL] [Abstract][Full Text] [Related]
16. Detection of BRAFV600E by digital PCR on fine-needle aspirate enables rapid initiation of dabrafenib and trametinib in unresectable anaplastic thyroid carcinoma. Buffet C; Allard L; Guillerm E; Ghander C; Mathy E; Lussey-Lepoutre C; Julien N; Touma E; Quilhot P; Godiris-Petit G; Lacorte JM; Leenhardt L; Denis JA Eur J Endocrinol; 2022 Sep; 187(3):K33-K38. PubMed ID: 35900324 [TBL] [Abstract][Full Text] [Related]
17. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431 [TBL] [Abstract][Full Text] [Related]
18. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953 [No Abstract] [Full Text] [Related]
19. [Anaplastic thyroid carcinoma : new therapeutic approaches]. Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754 [TBL] [Abstract][Full Text] [Related]
20. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres. Lorimer C; Cheng L; Chandler R; Garcez K; Gill V; Graham K; Grant W; Sardo Infirri S; Wadsley J; Wall L; Webber N; Wong KH; Newbold K Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e60-e66. PubMed ID: 36379836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]